| Current Price | $29.21 | Mkt Cap | $1.6B |
|---|---|---|---|
| Open | $28.56 | P/E Ratio | 40.08 |
| Prev. Close | $28.56 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $28.56 - $29.80 | Volume | 411,003 |
| 52-Wk Range | $27.26 - $42.09 | Avg. Daily Vol. | 451,705 |
| Current Price | $29.21 | Mkt Cap | $1.6B |
|---|---|---|---|
| Open | $28.56 | P/E Ratio | 40.08 |
| Prev. Close | $28.56 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $28.56 - $29.80 | Volume | 411,003 |
| 52-Wk Range | $27.26 - $42.09 | Avg. Daily Vol. | 451,705 |
The best Bull and Bear pitches based on recency and number of recommendations.
Already done well with this but believe still some good upside if the two drugs still in development pan out (so far looks good but longer term / higher risk play until actually happens)In the meantime, approach of adding ER (extended release) to… More
Man, I wish I got in on this one just a few days earlier (IPO debut). Still, this is about as safe as a red thumb gets. Supernus has shareholders' equity of just $270,000 as of 1Q12, which registers as a fair book value of a whopping $0.0113 per… More
Read the most recent pitches from players about SUPN.
Recs
TMFjimhalley
(< 20)
Submitted: 3/21/2021 8:49:00 PM :
Start Price:
$25.49
NASDAQ:SUPN Score:
+5.78
Supernus is already growing revenue and will really take off if the company's ADHD therapy candidate, SPN-812, is approved this year, as expected.
Recs
Bigsef77
(48.40)
Submitted: 4/29/2020 2:54:00 PM :
Start Price:
$48.20
NASDAQ:SUPN Score:
-87.20
CNS portfolio acquisition
Recs
genedom
(91.35)
Submitted: 3/14/2019 3:27:37 PM :
Start Price:
$37.71
NASDAQ:SUPN Score:
-73.58
Good value at 38. Fair value should be 44-50. 4th P3 trial will be positive.
Find the members with the highest scoring picks in SUPN.
See what the Wall Street professionals think, according to their public statements and filings.
